^
    Back
    Association details:
    Biomarker:H3.3K27M
    Cancer:Glioma
    Drug:Farydak (panobinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Neurooncol
    Title:

    Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience

    Published date:
    01/25/2022
    Excerpt:
    We report our retrospective experience with use of panobinostat in adults (> 18 years) with H3 K27M-mutant DMG...The median overall survival was 42 months, median progression free survival of 19 months...The best response was stable disease in 2 patients and a partial response in 1 patient.
    DOI:
    10.1007/s11060-022-03950-8
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas

    Excerpt:
    ...in mice injected with H3.3K27M cell lines, combined administration of 5-azacytidine and panobinostat resulted in further improved survival compared to either drug delivered alone…
    Secondary therapy:
    azacitidine
    DOI:
    10.1016/j.ccell.2019.04.004